simvastatin has been researched along with Down Syndrome in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| DʼAcunto, K; Sismour, B | 1 |
| Caslake, M; Cooper, SA; Evans, J; Hassiotis, A; Jahoda, A; McConnachie, A; Morrison, J; Ring, H; Starr, J; Stiles, C; Sullivan, F | 1 |
| Hanratty, J; Livingstone, N; Macdonald, G; McShane, R | 1 |
| Ademola, T; Caslake, M; Cooper, SA; Douglas, E; Evans, J; Greenlaw, N; Haig, C; Hassiotis, A; Jahoda, A; McConnachie, A; Morrison, J; Ring, H; Sirisena, C; Starr, J; Stiles, C; Sullivan, F | 1 |
1 review(s) available for simvastatin and Down Syndrome
| Article | Year |
|---|---|
Pharmacological interventions for cognitive decline in people with Down syndrome.
Topics: Acetylcarnitine; Adult; Antioxidants; Cognition; Cognition Disorders; Donepezil; Down Syndrome; Humans; Indans; Memantine; Middle Aged; Nootropic Agents; Piperidines; Randomized Controlled Trials as Topic; Simvastatin | 2015 |
2 trial(s) available for simvastatin and Down Syndrome
| Article | Year |
|---|---|
Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial.
Topics: Age of Onset; Alzheimer Disease; Cognition Disorders; Down Syndrome; Feasibility Studies; Humans; Hypolipidemic Agents; Middle Aged; Neuropsychological Tests; Pilot Projects; Primary Prevention; Qualitative Research; Research Design; Simvastatin | 2014 |
Towards onset prevention of cognition decline in adults with Down syndrome (The TOP-COG study): A pilot randomised controlled trial.
Topics: Adult; Cognitive Dysfunction; Double-Blind Method; Down Syndrome; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pilot Projects; Prospective Studies; Simvastatin | 2016 |
1 other study(ies) available for simvastatin and Down Syndrome
| Article | Year |
|---|---|
Down syndrome, severe psoriasis, and increased risk for cardiovascular events.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Down Syndrome; Fatal Outcome; Female; Heart Septal Defects; Humans; Hyperlipidemias; Hypolipidemic Agents; Interferon-gamma; Metoprolol; Middle Aged; Myocardial Infarction; Polycythemia; Psoriasis; Risk Factors; Severity of Illness Index; Simvastatin; Triamcinolone Acetonide | 2019 |